Evidence map›Paper›PMID 39351138›Full record

ArticleJournal of biomedical optics2024

Simultaneous assessment of NAD(P)H and flavins with multispectral fluorescence lifetime imaging microscopy at a single excitation wavelength of 750 nm.

Boris Yakimov, Anastasia Komarova, Elena Nikonova, Artem Mozherov, Liubov Shimolina, Marina Shirmanova, Wolfgang Becker, Evgeny Shirshin, Vladislav Shcheslavskiy

Abstract read
In one paragraph

Article in Journal of biomedical optics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Boris YakimovSechenov First Moscow State Medical University, Laboratory of Clinical Biophotonics, Moscow, Russia.
Anastasia KomarovaPrivolzhsky Research Medical University, Institute of Experimental Oncology and Biomedical Technologies, Novgorod, Russia.
Elena NikonovaSechenov First Moscow State Medical University, Laboratory of Clinical Biophotonics, Moscow, Russia.
Artem MozherovPrivolzhsky Research Medical University, Institute of Experimental Oncology and Biomedical Technologies, Novgorod, Russia.
Liubov ShimolinaPrivolzhsky Research Medical University, Institute of Experimental Oncology and Biomedical Technologies, Novgorod, Russia.
Marina ShirmanovaPrivolzhsky Research Medical University, Institute of Experimental Oncology and Biomedical Technologies, Novgorod, Russia.ORCID 0000-0002-3207-7227
Wolfgang BeckerBecker&Hickl GmbH, Berlin, Germany.
Evgeny ShirshinSechenov First Moscow State Medical University, Laboratory of Clinical Biophotonics, Moscow, Russia.
Vladislav ShcheslavskiyPrivolzhsky Research Medical University, Institute of Experimental Oncology and Biomedical Technologies, Novgorod, Russia.ORCID 0000-0003-3253-8211

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Significance: Autofluorescence characteristics of the reduced nicotinamide adenine dinucleotide and oxidized flavin cofactors are important for the evaluation of the metabolic status of the cells. The approaches that involve a detailed analysis of both spectral and time characteristics of the autofluorescence signals may provide additional insights into the biochemical processes in the cells and biological tissues and facilitate the transition of spectral fluorescence lifetime imaging into clinical applications. Aim: We present the experiments on multispectral fluorescence lifetime imaging with a detailed analysis of the fluorescence decays and spectral profiles of the reduced nicotinamide adenine dinucleotide and oxidized flavin under a single excitation wavelength aimed at understanding whether the use of multispectral detection is helpful for metabolic imaging of cancer cells. Approach: We use two-photon spectral fluorescence lifetime imaging microscopy. Starting from model solutions, we switched to cell cultures treated by metabolic inhibitors and then studied the metabolism of cells within tumor spheroids. Results: The use of a multispectral detector in combination with an excitation at a single wavelength of 750 nm allows the identification of fluorescence signals from three components: free and bound NAD(P)H, and flavins based on the global fitting procedure. Multispectral data make it possible to assess not only the lifetime but also the spectral shifts of emission of flavins caused by chemical perturbations. Altogether, the informative parameters of the developed approach are the ratio of free and bound NAD(P)H amplitudes, the decay time of bound NAD(P)H, the amplitude of flavin fluorescence signal, the fluorescence decay time of flavins, and the spectral shift of the emission signal of flavins. Hence, with multispectral fluorescence lifetime imaging, we get five independent parameters, of which three are related to flavins. Conclusions: The approach to probe the metabolic state of cells in culture and spheroids using excitation at a single wavelength of 750 nm and a fluorescence time-resolved spectral detection with the consequent global analysis of the data not only simplifies image acquisition protocol but also allows to disentangle the impacts of free and bound NAD(P)H, and flavin components evaluate changes in their fluorescence parameters (emission spectra and fluorescence lifetime) upon treating cells with metabolic inhibitors and sense metabolic heterogeneity within 3D tumor spheroids.

Indexed as

FlavinsNADPCell Line, TumorHumansMicroscopy, FluorescenceMicroscopy, Fluorescence, MultiphotonNADSpheroids, CellularFlavinsNADNADPflavinsfluorescence lifetime imagingmetabolismmicroscopyNAD(P)Htime-correlated single photon counting

Identifiers

PMID39351138
PMCPMC11440180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.